Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024
16 déc. 2024 06h00 HE
|
Serina Therapeutics, Inc.
Meet with Serina’s CEO Steven A. LedgerParkinson's disease is a progressive neurological disorder that primarily affects movementContinuous dopaminergic stimulation (CDS) has been shown to reduce the...
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
11 déc. 2024 06h05 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
12 nov. 2024 17h00 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced...
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
11 nov. 2024 17h40 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for...
Serina Therapeutics to Present at the 14th Annual Injectables Summit
02 oct. 2024 08h30 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 18h42 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
29 juil. 2024 08h30 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug delivery...
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation
18 juil. 2024 17h00 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
14 mai 2024 16h05 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
26 mars 2024 17h04 HE
|
Serina Therapeutics
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the...